Elekta (OTCMKTS:EKTAY) Sees Large Volume Increase – Should You Buy?

Elekta AB (OTCMKTS:EKTAY – Get Free Report) shares saw an uptick in trading volume on Tuesday . 6,183 shares traded hands during trading, an increase of 106% from the previous session’s volume of 3,007 shares.The stock last traded at $5.1249 and had previously closed at $5.0490.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded shares of Elekta from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Elekta presently has an average rating of “Reduce”.

Get Elekta alerts:

Check Out Our Latest Report on Elekta

Elekta Trading Up 0.6%

The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.68 and a current ratio of 0.87. The business has a 50 day simple moving average of $5.24 and a 200-day simple moving average of $5.83. The stock has a market capitalization of $1.89 billion, a P/E ratio of -32.00 and a beta of 1.01.

Elekta (OTCMKTS:EKTAY – Get Free Report) last announced its quarterly earnings data on Thursday, May 28th. The company reported $0.06 earnings per share for the quarter. Elekta had a positive return on equity of 11.11% and a negative net margin of 3.32%.The business had revenue of $521.00 million during the quarter. On average, analysts predict that Elekta AB will post 0.43 EPS for the current year.

Elekta Company Profile

(Get Free Report)

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.

Further Reading

• Five stocks we like better than Elekta
• AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
• The AI Chip Blockade Is Creating a Shadow Market
• Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
• Reddit’s U.S. User Decline Raises a Bigger Question After Its Earnings Beat

Receive News & Ratings for Elekta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elekta and related companies with MarketBeat.com's FREE daily email newsletter.